Clinical trials
Trial starts, readouts, holds and designs.
Stories
-
Authors find no link between engraftment microbiome diversity and non-relapse mortality
The authors of a Phase III trial published in Nature Medicine reported no association between engraftment microbiome diversity and non-relapse mortality after 1 year (P = 0.314). They also found that lower baseline microbiome diversity was associated with shorter overall survival (P = 0.007).
-
Orphalan expands TRADITiONAL study into China, first participant randomised worldwide
Orphalan SA announced the expansion of its Phase 3 TRADITiONAL Study into China, marking the first participant worldwide randomised at The Second Affiliated Hospital of Zhejiang University School of Medicine. The study evaluates once-daily trientine tetrahydrochloride versus D-penicillamine over 48 weeks.
-
AbbVie registers Phase 2b/3 study of ABBV-2294 in systemic sclerosis
The study plans to enroll 580 participants at about 200 sites worldwide, with a planned start date of December 11, 2026. It plans to evaluate the safety and efficacy of the combination of ABBV-722 and upadacitinib versus placebo over 52 weeks with optional extension periods.
-
Pfizer registers Phase 3 trial of berobenatide in women with stress urinary incontinence and obesity
The study, titled VESPER-SUI, plans to enroll 900 participants and has a planned start date of November 17, 2026. It aims to learn about the safety and effectiveness of berobenatide in adult women with stress urinary incontinence and obesity or overweight.
-
Telix registers Phase 3 study of [18F]FET PET in brain metastases
The study, led by Telix Pharmaceuticals (Innovations) Pty Limited, plans to enroll 381 participants and begin in December 2026. It will evaluate whether [18F]Floretyrosine PET can differentiate tumor progression from treatment-related changes in patients with brain metastases and equivocal MRI findings.
-
Qilu Pharmaceutical registers Phase 3 trial of QLS4131 in relapsed or refractory multiple myeloma
The study, first posted on ClinicalTrials.gov on November 12, 2026, plans to enroll 300 participants and has a planned start date of December 30, 2026. It compares QLS4131 injection with the investigator's choice regimen in participants with relapsed or refractory multiple myeloma.
-
AstraZeneca registers Phase III trial of FDC laroprovstat/rosuvastatin in hypercholesterolemia
The study plans to enroll 204 participants and is expected to start on December 21, 2026. It aims to evaluate the effect on LDL-C and the safety and tolerability of the fixed-dose combination in lipid-lowering treatment-naïve patients.
-
Rhythm posts results of Phase 3 setmelanotide trial in genetic obesity
The study enrolled 296 participants and completed primary data collection on December 19, 2025. Results were first posted on ClinicalTrials.gov on November 12, 2026.
-
Hoffmann-La Roche posts results of Phase III obinutuzumab study in systemic lupus erythematosus
Results for the study were first posted on ClinicalTrials.gov on November 12, 2026. The Phase III trial enrolled 303 participants, with primary completion on September 15, 2025, and compared obinutuzumab to placebo in patients with active, autoantibody-positive systemic lupus erythematosus receiving standard-of-care therapy.
-
Pfizer posts results of Phase 3 gene therapy study in Duchenne Muscular Dystrophy
The study, a Phase 3 long-term safety and efficacy follow-up of fordadistrogene movaparvovec, enrolled 7 participants and was terminated. It began on March 13, 2023, with primary completion on September 24, 2025.
-
Argá Medtech completes enrollment of paroxysmal AF cohort in COHERENT-AF
The company announced that 150 intention-to-treat subjects were enrolled in the paroxysmal atrial fibrillation cohort across 27 sites in Europe and the United States. Enrollment of the persistent AF cohort is ongoing and expected to finish in the next two months.
-
Median overall survival 7.7 months on epcoritamab and 9.0 on chemotherapy in a China lymphoma trial
In a Phase 3 sub-study in China, median overall survival was 7.7 months with epcoritamab and 9.0 months with investigator's choice chemotherapy in relapsed or refractory DLBCL. Genmab has now posted randomized results for 72 participants.